Pharvaris (PHVS) Competitors $23.22 -0.13 (-0.55%) Closing price 03:59 PM EasternExtended Trading$23.18 -0.05 (-0.19%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. CYTK, VKTX, TGTX, KRYS, ACAD, PCVX, AAPG, ACLX, ADMA, and ZLABShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), Arcellx (ACLX), ADMA Biologics (ADMA), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Vaxcyte Ascentage Pharma Group International Arcellx ADMA Biologics Zai Lab Pharvaris (NASDAQ:PHVS) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership. Which has more risk & volatility, PHVS or CYTK? Pharvaris has a beta of -2.81, indicating that its stock price is 381% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Which has preferable valuation & earnings, PHVS or CYTK? Pharvaris has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$145.24M-$3.36-6.91Cytokinetics$18.47M248.16-$589.53M-$5.10-7.51 Does the media refer more to PHVS or CYTK? In the previous week, Pharvaris had 6 more articles in the media than Cytokinetics. MarketBeat recorded 22 mentions for Pharvaris and 16 mentions for Cytokinetics. Pharvaris' average media sentiment score of 0.81 beat Cytokinetics' score of 0.45 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 8 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 9 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PHVS or CYTK more profitable? Pharvaris has a net margin of 0.00% compared to Cytokinetics' net margin of -707.17%. Cytokinetics' return on equity of 0.00% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -69.09% -63.34% Cytokinetics -707.17%N/A -45.52% Do analysts prefer PHVS or CYTK? Pharvaris currently has a consensus price target of $35.60, suggesting a potential upside of 53.31%. Cytokinetics has a consensus price target of $71.58, suggesting a potential upside of 86.88%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93 SummaryCytokinetics beats Pharvaris on 8 of the 14 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21B$3.09B$5.83B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-6.9121.1631.1625.99Price / SalesN/A396.94474.86122.97Price / CashN/A43.0937.1558.38Price / Book5.818.069.116.38Net Income-$145.24M-$54.72M$3.26B$265.56M7 Day Performance4.13%2.52%2.06%1.89%1 Month Performance0.44%7.54%5.08%1.23%1 Year Performance27.52%13.01%31.26%21.10% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris2.6439 of 5 stars$23.22-0.6%$35.60+53.3%+31.3%$1.21BN/A-6.9130CYTKCytokinetics3.6123 of 5 stars$38.95+0.7%$71.58+83.8%-32.8%$4.63B$18.47M-7.64250News CoverageVKTXViking Therapeutics4.0243 of 5 stars$42.09+5.1%$86.92+106.5%-60.4%$4.50BN/A-27.5120Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3598 of 5 stars$27.73-1.2%$46.25+66.8%+14.8%$4.46B$329M74.95290Positive NewsKRYSKrystal Biotech4.7396 of 5 stars$146.30-2.6%$210.75+44.1%-27.7%$4.35B$290.52M29.74210News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals3.9511 of 5 stars$25.06-1.1%$28.88+15.2%+55.6%$4.27B$1.02B18.84510Insider TradePCVXVaxcyte2.5594 of 5 stars$32.09-1.9%$136.50+325.4%-60.0%$4.25BN/A-7.81160News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$47.49+5.6%N/AN/A$4.18B$134.35M0.00600News CoverageACLXArcellx2.1831 of 5 stars$71.82-3.1%$114.31+59.2%+7.7%$4.11B$107.94M-21.0080Positive NewsADMAADMA Biologics4.3739 of 5 stars$17.63+3.8%$27.67+56.9%-4.1%$4.05B$474.17M20.50530Positive NewsZLABZai Lab2.8362 of 5 stars$35.69-0.1%$57.22+60.3%+94.2%$3.97B$398.99M-17.501,869News CoverageInsider Trade Related Companies and Tools Related Companies Cytokinetics Alternatives Viking Therapeutics Alternatives TG Therapeutics Alternatives Krystal Biotech Alternatives ACADIA Pharmaceuticals Alternatives Vaxcyte Alternatives Ascentage Pharma Group International Alternatives Arcellx Alternatives ADMA Biologics Alternatives Zai Lab Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access